Review by Dr. Thomas Kingsley Brown is the most complete known summary of the medical uses of ibogaine
Beond, a patient-centered clinical practice specializing in ibogaine treatment for opioid detox and rehabilitation, is pleased to announce that it has published a comprehensive clinical summary of ibogaine use and treatments for the benefit of researchers and medical practitioners. This resource was created in collaboration with anthropologist and ibogaine therapy expert Thomas Kingsley Brown, Ph.D.
Citing an extensive body of peer-reviewed research, the resulting document is the most complete and up-to-date known summary of the medical uses of ibogaine. The summary includes thorough discussions of what is currently known about ibogaine’s effectiveness for a variety of indications, especially opioid and opiate addiction; sources of ibogaine and methods of administration; reported experiential effects; safety and known side effects; and pharmacology.
“Ibogaine is the only treatment for opioid use disorder that consistently and significantly alleviates withdrawal symptoms that isn’t itself an opioid, and it does so with an effect level on par with methadone,” said Dr. Brown, author of the clinical summary. “Research also shows that ibogaine not only interrupts addiction in the short term but also helps people control their drug addiction in the long term, leading to cessation or substantial reductions in problematic drug use,” Dr. Brown added.
With increased interest in psychedelic medicines for the treatment of addiction and other mental health conditions, Beond and Dr. Brown have made this clinical summary free and publicly available for the benefit of prospective patients, practitioners, and the professional research community.
“We understand that for many people the decision of whether or not to utilize ibogaine-assisted treatment for chemical dependency or severe depression, anxiety, or trauma can be daunting” said Tom Feegel, co-founder of Beond. “Many of our clients report that this process can take months of research, leaving them to depend on claims from unverifiable sources, and can even lead to conflicting conclusions based on partial or incomplete information. Beond believes this outcome does a disservice to everyone seeking to understand Ibogaine and its potential benefits, and we seek to be a reliable, accessible resource for anyone seeking information about this powerful treatment.”
Beond has previously hosted educational events with similar objectives, in partnership with other renowned researchers, including Dr. Gabor Maté.
Beond’s “Ibogaine: A Clinical Summary” is available in its entirety, free of charge, on the Beond website.
Those interested in interviewing Dr. Thomas Kingsley Brown or Tom Feegel are invited to contact:
Brad Burge
Integration Communications
brad@integrationcommunications.com
About Beond
Beond is the first-ever network of psychedelic therapy clinics specializing in ibogaine treatment for addiction and trauma. Its flagship clinic based in Mexico, Beond provides a unique five-phase treatment model called Insight-Oriented Ibogaine, which includes preparation, pre-treatment care, ibogaine treatment, and post-treatment and long term aftercare plans. The model supports each client’s specific needs and intentions by combining leading medical and mental health professionals, beautiful natural surroundings, and world-class ibogaine-assisted therapy.
About Thomas Kingsley Brown, Ph.D.
Dr. Thomas Kingsley Brown is a prominent researcher into the effects of altered states of consciousness on behavioral health conditions, and has been investigating ibogaine treatment since 2009. He has studied the impact of ibogaine on quality of life when used for the treatment of behavioral conditions, and conducted an observational study of the long-term outcomes of ibogaine-assisted treatment for substance dependence. He has a B.S. in chemistry from the University of Pittsburgh, an M.S. from the California Institute of Technology, and a Ph.D. in anthropology from UC San Diego, where he administers a research program for students interested in pursuing doctoral degrees.
Citing an extensive body of peer-reviewed research, the resulting document is the most complete and up-to-date known summary of the medical uses of ibogaine. The summary includes thorough discussions of what is currently known about ibogaine’s effectiveness for a variety of indications, especially opioid and opiate addiction; sources of ibogaine and methods of administration; reported experiential effects; safety and known side effects; and pharmacology.
“Ibogaine is the only treatment for opioid use disorder that consistently and significantly alleviates withdrawal symptoms that isn’t itself an opioid, and it does so with an effect level on par with methadone,” said Dr. Brown, author of the clinical summary. “Research also shows that ibogaine not only interrupts addiction in the short term but also helps people control their drug addiction in the long term, leading to cessation or substantial reductions in problematic drug use,” Dr. Brown added.
With increased interest in psychedelic medicines for the treatment of addiction and other mental health conditions, Beond and Dr. Brown have made this clinical summary free and publicly available for the benefit of prospective patients, practitioners, and the professional research community.
“We understand that for many people the decision of whether or not to utilize ibogaine-assisted treatment for chemical dependency or severe depression, anxiety, or trauma can be daunting” said Tom Feegel, co-founder of Beond. “Many of our clients report that this process can take months of research, leaving them to depend on claims from unverifiable sources, and can even lead to conflicting conclusions based on partial or incomplete information. Beond believes this outcome does a disservice to everyone seeking to understand Ibogaine and its potential benefits, and we seek to be a reliable, accessible resource for anyone seeking information about this powerful treatment.”
Beond has previously hosted educational events with similar objectives, in partnership with other renowned researchers, including Dr. Gabor Maté.
Beond’s “Ibogaine: A Clinical Summary” is available in its entirety, free of charge, on the Beond website.
Those interested in interviewing Dr. Thomas Kingsley Brown or Tom Feegel are invited to contact:
Brad Burge
Integration Communications
brad@integrationcommunications.com
About Beond
Beond is the first-ever network of psychedelic therapy clinics specializing in ibogaine treatment for addiction and trauma. Its flagship clinic based in Mexico, Beond provides a unique five-phase treatment model called Insight-Oriented Ibogaine, which includes preparation, pre-treatment care, ibogaine treatment, and post-treatment and long term aftercare plans. The model supports each client’s specific needs and intentions by combining leading medical and mental health professionals, beautiful natural surroundings, and world-class ibogaine-assisted therapy.
About Thomas Kingsley Brown, Ph.D.
Dr. Thomas Kingsley Brown is a prominent researcher into the effects of altered states of consciousness on behavioral health conditions, and has been investigating ibogaine treatment since 2009. He has studied the impact of ibogaine on quality of life when used for the treatment of behavioral conditions, and conducted an observational study of the long-term outcomes of ibogaine-assisted treatment for substance dependence. He has a B.S. in chemistry from the University of Pittsburgh, an M.S. from the California Institute of Technology, and a Ph.D. in anthropology from UC San Diego, where he administers a research program for students interested in pursuing doctoral degrees.
